Integrative and Comprehensive Pan-Cancer Analysis of Lymphocyte-Specific Protein Tyrosine Kinase in Human Tumors

• Published in: International journal of molecular sciences Vol. 23; no. 22; p. 13998
• Main Authors: Han, Mingwei, Li, Yiming, Guo, Yixiao, Zhu, Wanwan, Jiang, Jianli
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 13.11.2022; MDPI
• Subjects: Annotations; Breast cancer; Cancer; Cell Line, Tumor; Clinical outcomes; Diagnostic systems; DNA methylation; Drug development; Gene expression; Genomes; Humans; Kinases; LCK; Lck protein; Leukemia; LIHC; LUAD; Lymphocyte Specific Protein Tyrosine Kinase p56(lck) - genetics; Lymphocyte Specific Protein Tyrosine Kinase p56(lck) - metabolism; Lymphocytes; Lymphocytes - metabolism; Lymphocytes T; Malignancy; Medical prognosis; Melanoma; Metastases; Mutation; Neoplasms - genetics; Ovarian cancer; pan-cancer analysis; Patients; PD-L1 protein; Protein-tyrosine kinase; Proteins; Signal transduction; Solid tumors; T cell receptors; TCGA; Tumor cell lines; Tumors; Tyrosine; Western blotting; LIHC; LCK; TCGA; LUAD; pan-cancer analysis
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms232213998

Lymphocyte-specific protein tyrosine kinase (LCK) is common in a variety of hematologic malignancies but comparatively less common in solid tumors. This study aimed to explore the potential diagnostic and prognostic value of LCK across tumors through integrative and comprehensive pan-cancer analysis, as well as experimental validation. Multiple databases were used to explore the expression, alteration, prognostic value, association with immune infiltration, and potential functional pathways of LCK in pan-cancers. The results were further validated by western blotting and qPCR of patient samples as well as tumor cell lines. High LCK expression typically represents a better prognosis. Notably, drug sensitivity prediction of LCK identified P-529 as a candidate for drug development. Gene Annotations (GO) and KEGG analyses showed significant enrichment of PD-L1 and the T-cell receptor pathway. The results from patient samples and tumor cell lines confirmed these conclusions in LIHC. In conclusion, LCK is differentially expressed in multiple tumors and normal tissues. Further analysis highlighted its association with prognostic implications, pan-cancer genetic alterations, and immune signatures. Our data provide evidence for a diagnostic marker of LCK and the possible use of LCK as a target for the treatment of tumors.